Research programme: anti-fibrotic agents - Pfizer

Drug Profile

Research programme: anti-fibrotic agents - Pfizer

Alternative Names: UK-383,367; UK-421,045

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Hydroxamic acids; Oxadiazoles; Sulfonamides
  • Mechanism of Action Bone morphogenetic protein receptor type I antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Scars

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Scars in United Kingdom (Topical)
  • 05 Aug 2009 This programme is in active development
  • 28 Aug 2007 Preclinical data added to the pharmacokinetics and Skin Disorders pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top